Bened Biomedical Featured in Los Angeles Times Special Report
- enchia
- 5 days ago
- 2 min read
We are pleased to announce that Bened Biomedical has been featured in a recent Los Angeles Times Special Report on Taiwan's technological innovation. The comprehensive article highlights our company's groundbreaking work in psychobiotics and our growing global impact in addressing neurological health challenges.
Pioneering Psychobiotics Leadership
The LA Times report recognizes Bened Biomedical as one of the top three companies worldwide in the rapidly expanding psychobiotics industry. Founded in 2015 by Professor Ying-Chieh Tsai from National Yang-Ming University and our Chairman and CEO Frankie Cheng, along with Executive Director Enchia Tsai, our company has established itself as a leader in gut-brain axis research.
The article spotlights our flagship strain, L. plantarum PS128, which was isolated from fermented vegetables in Professor Tsai's laboratory. Through extensive research into the gut-brain axis (GBA), we've developed this unique psychobiotic to support conditions such as autism, anxiety, and Parkinson's disease.
Remarkable Growth and Global Expansion
The LA Times report highlights our impressive 80% growth in revenue over the past year. As noted in the article, our differentiated approach has enabled us to establish a strong presence in more than 60 countries, meeting the growing global demand for evidence-based, natural solutions for neurological health.
"L. plantarum PS128 is unique, and effective in supporting the gut-brain axis," our Chairman Frankie Cheng explained in the feature. This unique positioning has helped Bened Biomedical meet the needs of diverse communities seeking effective neurological health support worldwide.
Strong U.S. Market Presence
A significant portion of the LA Times article focuses on our successful expansion into the United States. In 2022, we acquired Oryx Biomedical, now operating as Bened Life, which offers the medical food Neuralli MP featuring our proprietary probiotic L. plantarum PS128.
The report highlights that Bened Life has grown to contribute 40% of our total revenue, making the U.S. our largest market. David Lee, Chief Operating Officer of Bened Life, was quoted in the article: "There are diverse communities of people with unmet neurological and mental health needs that are looking for effective options to support their health or the health of loved ones. At Bened Life, we believe that safe and effective microbiome solutions are part of the answer."
The article also notes that many Bened Life employees are neurodivergent themselves or have family members who are neurodivergent or living with neurological conditions, giving us unique insights into the communities we serve.
Commitment to Quality and Innovation
The LA Times feature recognizes our unwavering commitment to quality and scientific advancement. Our strategic decision to base operations in Taipei Bioinnovation Park—a hub for leading biotech firms—illustrates our commitment to remaining at the forefront of scientific advancement while fostering an environment of collaboration and growth.
As we celebrate our 10-year anniversary, Bened Biomedical remains dedicated to creating transformative solutions for individuals with neurological conditions. This recognition by the Los Angeles Times affirms our mission and the positive impact our products are making in communities around the world.
We invite you to read the full feature in the Los Angeles Times Taiwan Special Report, and we thank our customers, partners, and supporters who have been part of our journey to improve neurological health through innovative psychobiotic solutions.
For more information about our products and research, please explore our website or contact our team directly.